Kyushu Communication: Subsidiary's drug Haloperidol Hydrochloride Injection obtained registration certificate.

Notice from Kyushu Corporation, on December 25, 2025, the subsidiary company Beijing Jingfeng Pharmaceutical Group Co., Ltd.'s affiliate company Huiyu Yuanhe Pharmaceutical Co., Ltd. received the "Drug Registration Certificate" issued by the National Medical Products Administration for the injection solution of promethazine hydrochloride. Promethazine hydrochloride injection solution is an antihistamine drug, used for skin and mucosal allergies, motion sickness, adjunctive therapy for anesthesia and before and after surgery, prevention and treatment of radiation-induced or drug-induced nausea and vomiting. As of the date of this announcement, Huiyu Yuanhe has invested approximately 4.67 million yuan in research and development expenses for this drug.